ANIK Anika Therapeutics Inc.

45.89
+0.46  (+1%)
Previous Close 45.43
Open 46.6
Price To Book 2.33
Market Cap 654,821,252
Shares 14,269,367
Volume 235,996
Short Ratio
Av. Daily Volume 158,060
Stock charts supplied by TradingView

NewsSee all news

  1. Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group

    STOUGHTON, Mass., Jan. 13, 2020 /PRNewswire/ -- Primo Medical Group, a Massachusetts based medical device manufacturer and incubator, is pleased to announce the sale of its spin-off company Arthrosurface, to Anika

  2. Anika Therapeutics to Acquire Parcus Medical and Arthrosurface

    Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Conference Call & Webcast January 8 at 8:30 a.m. ET Anika

  3. Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it

  4. Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    SAN DIEGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DAR), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held

  5. Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020.
Cingal
Osteoarthritis
Approved Feb 2014
Monovisc
Osteoarthritis
Phase 3 enrollment to be completed by the end of 2018.
HYALOFAST
Cartilage defects of the knee

Latest News

  1. Sale of Global Leader in Joint Preservation Incubated at Primo Medical Group

    STOUGHTON, Mass., Jan. 13, 2020 /PRNewswire/ -- Primo Medical Group, a Massachusetts based medical device manufacturer and incubator, is pleased to announce the sale of its spin-off company Arthrosurface, to Anika

  2. Anika Therapeutics to Acquire Parcus Medical and Arthrosurface

    Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Conference Call & Webcast January 8 at 8:30 a.m. ET Anika

  3. Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it

  4. Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    SAN DIEGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DAR), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held

  5. Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced its

  6. Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 Fortius International Sports Injury Conference

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform, today

  7. Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs

    Industry veteran brings extensive experience leading global regulatory, quality, and clinical affairs teams Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated company, focused on developing regenerative

  8. Anika to Issue Third-quarter 2019 Financial Results and Business Highlights on Thursday, October 24

    Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that the Company plans to issue its third-quarter 2019 financial results after the close of the market on Thursday, October 24, 2019 and hold its investor

  9. Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 World Congress of the International Cartilage Regeneration and Joint Preservation Society

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated regenerative therapies company leveraging its proprietary hyaluronic acid ("HA") technology platform, today announced plans to showcase its

  10. Sharps Compliance Adds Susan Vogt to Board of Directors

    HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (NASDAQ:SMED) ("Sharps" or the "Company"), a leading full-service national provider of comprehensive waste management solutions including medical,

  11. Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid ("HA") technology platform to provide therapies across the Joint Preservation

  12. Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it will

  13. Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019

    Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced